George A. Follows

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Polyclonal B-cell lymphocytosis: a rare, benign condition that mimics a chronic lymphoproliferative disorder.

Polyclonal B-cell lymphocytosis: a rare, benign condition that mimics a chronic lymphoproliferative disorder.

Journal: Hematology (Amsterdam, Netherlands)

Published: July 30, 2026

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Journal: Haematologica

Published: January 21, 2026

Author Correction: The long-term effects of chemotherapy on normal blood cells.

Author Correction: The long-term effects of chemotherapy on normal blood cells.

Journal: Nature genetics

Published: July 31, 2025

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 29, 2025

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 27, 2025

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 06, 2025

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: May 05, 2025

Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series.

Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series.

Journal: Clinical case reports

Published: March 19, 2025

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Journal: Leukemia

Published: December 03, 2024

The long-term effects of chemotherapy on normal blood cells.

The long-term effects of chemotherapy on normal blood cells.

Journal: Nature genetics

Published: September 11, 2024

Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.

Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.

Journal: British journal of haematology

Published: August 23, 2024

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Journal: Blood

Published: August 21, 2024

Showing 1-12 of 86

Last Updated: 09/26/2026